We are extremely proud that our central involvement in designing, execution and analysis of the Telix ZIRCON pivotal phase III study was recently recognised in The Lancet Oncology.
This prospective, open-label, multicentre study evaluated the clinical utility of [⁸⁹Zr]Zr-girentuximab PET–CT imaging for detection and characterisation of clear-cell renal cell carcinoma.
While the study design was authored by Dr. Andreas Kluge, founder of ABX-CRO, Dr. Volker Meyer, Director Clinical Operations, was significantly involved in planning and realisation of this first-ever conducted pivotal PET study with an 89Zr-labelled diagnostic antibody. Our dedicated Image Core Lab team, headed by Karl Schmidt was responsible for state-of-the-art image analysis.
We thank Telix pharmaceuticals for choosing ABX-CRO for this historical PET diagnostic trial and are delighted to see this work being published in one of the world’s highest-impact academic journals.
Read the full article here